Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)

$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd at NWR Healthcare Conference (Virtual) Transcript
Mar 22, 2023
Paradigm Biopharmaceuticals Ltd Annual Shareholders Meeting Transcript
Nov 29, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Oct 04, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Aug 15, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Jul 21, 2022
Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Paradigm Biopharmaceuticals Ltd Corporate Call Transcript
Aug 05, 2021
Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Paradigm Biopharmaceuticals Ltd Inaugural R&D Day Transcript
Dec 21, 2020
Paradigm Biopharmaceuticals Ltd Investor Call (Virtual) Transcript
Apr 08, 2020
Paradigm Biopharmaceuticals Ltd at NWR Communications Virtual Small Cap Investor Conference Transcript
Mar 26, 2020

Paradigm Biopharmaceuticals Ltd Corporate Call Transcript

Aug 05, 2021 / NTS GMT

Release Date Price: $1.59

Transcript

Paul Rennie

Paradigm Biopharmaceuticals Limited - CEO

Good morning, ladies and gentlemen. My name is Paul Rennie, CEO of Paradigm Biopharmaceuticals Limited. I'd like to welcome you all to Paradigm's investor update to discuss the recent response from the US FDA.

Today's meeting is being held online via the Lumi platform, where attendees can watch a live webcast of the meeting. In addition, shareholders have the ability to ask questions, which will be answered following the presentation. Questions can be submitted at any time throughout the presentation. (Conference Instructions)

Next slide, please. A standard disclaimer applies to this presentation.

Now, from my perspective, I see the situation with the FDA as progressing from six questions down to, now, one question for Paradigm to answer. And we are very confident that we can respond to the FDA within the month. I would now like to hand over to my colleague, Dr. Donna Skerrett, who is Paradigm's Chief Medical Officer, who will take you through a presentation, which will take between 15 and 20 minutes.

After the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.